Navigation Links
Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
Date:9/17/2009

HAYWARD, Calif., Sept. 17 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the start of enrollment for a phase 2 study comparing its proprietary drug candidate ITCA 650 (DUROS continuous delivery of exenatide) with Byetta, an FDA-approved twice-daily injection form of exenatide. Building upon the successful completion of a 28-day phase 1b study of ITCA 650 in May of this year, the phase 2 study is intended to evaluate the doses achieving the best results in the phase 1b in a larger study population and for a longer duration of treatment. In addition, an extension phase of the phase 2 study will evaluate dose response of ITCA 650. Patients receiving Byetta for the first 12 weeks will be switched from Byetta to one of two doses of ITCA 650 to evaluate the potential for improving treatment effect.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO)

"We are very pleased with the rapid progress and positive results achieved thus far in the ITCA 650 program" said Ken Luskey, MD, VP, Clinical Research for Intarcia. "In 2009, we expect to move the ITCA 650 program from IND-filing through completion of phase 2 enrollment."

The ITCA 650 phase 2 study will involve 150 patients with sub-optimally controlled type 2 diabetes treated with metformin. Patients will be recruited at 50 clinical trial sites in the US and will be randomized equally to receive one of two doses of ITCA 650 or twice-daily injections of Byetta. Upon completion of the 12-week course of treatment, patients on all three arms will be further randomized to receive higher doses of ITCA 650 for an additional 12 weeks. The extension phase will evaluate efficacy and tolerability of higher doses of ITCA 650, as well as the effects of switching patients from twice-daily injec
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
2. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
6. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
7. Nile Therapeutics, Inc. Adds to Executive Management Team
8. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
9. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
10. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
11. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... (PRWEB) July 23, 2014 International research ... announced that its biobanking project, Provia Laboratories , ... its growing Advisory Board. Scott Wolf , CEO ... have Dr. Vaught onboard with Provia’s ever-expanding Advisory Board. ... that Provia’s management team brings to this field, should ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire-iReach/ -- Think Drinks are ... for the long term. They are the first functional ... sustained energy as an alternative to the temporary fix ... on Indiegogo on July 29, 2014, with hopes to ... Photo - http://photos.prnewswire.com/prnh/20140723/129697 ...
(Date:7/23/2014)... de julio de 2014 ADB International ... ha anunciado hoy una asociación con Austen BioInnovation ... o el Instituto), para el propósito de llevar ... terapia de señal bioeléctrica (el E-QURE BST Device), ... que tiene una importante experiencia en cicatrización de ...
(Date:7/23/2014)... BRUSSELS , July 23, 2014 regulated ... its research and development pipeline with positive topline ... brivaracetam . This study was designed to evaluate ... (100 and 200 mg/day, without titration) compared to ... patients with partial-onset seizures, not fully controlled despite ...
Breaking Biology Technology:Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7
... Entomologists at the University of California, Riverside working on ... of compounds that could pave the way for developing inexpensive ... other deadly tropical diseases. When fruit flies undergo stress, ... a warning to other fruit flies that danger or predators ...
... HARBIN, China, Aug. 26 ... One Medical" or "the Company") (Nasdaq: ... over-the-counter,drugs in the People,s Republic of China ("PRC"), ... been raised with respect to financial reports filed,with ...
... , PARIS, August 26 , - Net Profit Up 11%, - Strong Research ... The Board of Directors, meeting on 25 August 2009 under the chairmanship,of Albert Saporta approved the 2009 half year financial ... 08/07 H1 2009, ... Var.% %CA, Sales ...
Cached Biology Technology:Discovery of natural odors could help develop mosquito repellents 2Discovery of natural odors could help develop mosquito repellents 3China Sky One Medical, Inc. Responds to Concerns Regarding Filed Financial Reports 2China Sky One Medical, Inc. Responds to Concerns Regarding Filed Financial Reports 3STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations 2STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations 3STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations 4
(Date:7/23/2014)... The U.S. Environmental Protection Agency (EPA) today announced ... University of Massachusetts Amherst School of Public Health ... $700,000 Science to Achieve Results (STAR) grant to ... Native subsistence hunters in subarctic North America to ... and to provide culturally-relevant recommendations for mitigation. , ...
(Date:7/23/2014)... Mass. Honey bees, especially the young, are highly ... work together to maintain temperatures within a narrow range. ... biologist at Tufts University,s School of Arts and Sciences, ... excess heat within a hive in process similar to ... blood vessels and skin. , "This study shows ...
(Date:7/23/2014)... cultured from cystic fibrosis patients, scientists at the UNC ... have shown that a new CF drug counteracts the ... The finding, published today in the journal Science ... becomes unstable and loses its ability to function properly ... research offers several insights into how novel CF pharmacotherapies ...
Breaking Biology News(10 mins):Studying impacts of indoor air pollution on tribal communities 2Studying impacts of indoor air pollution on tribal communities 3How honey bees stay cool 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 4
... in extreme cold, scientists no longer have to go ... Bacteria previously isolated from polar climates, and have properties ... been isolated from soil in temperate environments. , Professor ... have developed a technique to isolate bacteria which have ...
... the four bacterial surface proteins that generate the ... University of Chicago have created a vaccine that ... strains of Staphylococcus aureus, the most common cause ... of community-associated illness. , The vaccine protected ...
... The repeated copying of a small segment of DNA in ... to the transition of ancient animals from sea to land, ... discovery is "tantalizing evidence" that copied DNA elements known as ... the director of the research, Howard Hughes Medical Institute investigator ...
Cached Biology News:MRSA vaccine shows promise in mouse study 2MRSA vaccine shows promise in mouse study 3Mobile DNA part of evolution's toolbox 2Mobile DNA part of evolution's toolbox 3Mobile DNA part of evolution's toolbox 4
... Works fast and effectively in tubes and ... and simple, one tube, one and a half ... to clean up or concentrate any type of ... primers, primer dimers or dNTPs (labelled or unlabelled). ...
... holds 96 x 0.2 ml tubes or ... incorporates a thumbwheel to adjust height and ... oil-free cycling. Peltier heat pumps produce uniform, ... rates of up to 1.4 degrees C ...
... Detectors provide unmatched value and flexibility ... automation needs. Capable of performing fluorescence, ... same instrument, the DTX Series can ... be integrated seamlessly with Beckman Coulters ...
Sf21 Insect Cells (Live) in Max-XP Medium...
Biology Products: